ARCUTIS BIOTHERAPEUTICS, INC. Cash and Restricted Cash
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) had Cash and Restricted Cash of $34.43 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $34.43M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35.07M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $43.22M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $47.43M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $34.43M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $35.07M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $43.22M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $47.43M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $73.05M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $53.72M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $71.95M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $135.47M 10-Q · filed 2025-10-28 |
| 2024-06-30 | $84.89M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $190.71M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $89.32M 10-K · filed 2026-02-25 |
| 2023-09-30 | $108.40M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $106.04M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $82.33M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $54.88M 10-K · filed 2026-02-25 |
| 2022-09-30 | $82.78M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $62.74M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $71.03M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $97.99M 10-K · filed 2025-02-25 |
| 2021-09-30 | $53.32M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $90.67M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $290.23M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $66.62M 10-K · filed 2024-02-27 |
| 2020-09-30 | $45.71M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $171.55M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $190.89M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $63.34M 10-K · filed 2023-02-28 |
| 2019-09-30 | $23.18M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $12.82M 10-Q · filed 2020-08-11 |
| 2019-03-31 | $23.05M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $39.39M 10-K · filed 2022-02-22 |
| 2017-12-31 | $3.42M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |